Despite the extensive research efforts directed toward these two prominent hypotheses, therapeutic strategies targeting either amyloid-beta or tau have yielded limited success, underscoring the complex and multifactorial nature of Alzheimer’s disease (González et al., 2023). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.